Sarepta Therapeutics: A $2B Business Priced Like It's Broken
Corroborated by 1 source from 1 publisher
globalbusiness3h ago
TL;DR
According to seekingalpha.com, thesis Strategically, I think Sarepta Therapeutics, Inc.'s (SRPT) story is now going to be a fine balance between execution risk and long-term optionality.